CoChat
Sign Up
Cited by 876Dialysis and Renal Disease ManagementChronic Kidney Disease and DiabetesOrgan Donation and Transplantation

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy

Open access
Thurlow, John S., Joshi, Megha, Yan, Guofen, Norris, Keith C., Agodoa, Lawrence Y., Yuan, Christina M., Nee, Robert·2021·American Journal of Nephrology
DOI 10.1159/000514550PMC PMC8057343
Open this paper in CoChat — free account

Abstract

Background: The global epidemiology of end-stage kidney disease (ESKD) reflects each nation’s unique genetic, environmental, lifestyle, and sociodemographic characteristics. The response to ESKD, particularly regarding kidney replacement therapy (KRT), depends on local disease burden, culture, and socioeconomics. Here, we explore geographic variation and global trends in ESKD incidence and prevalence and examine variations in KRT modality, practice patterns, and mortality. We conclude with a discussion on disparities in access to KRT and strategies to reduce ESKD global burden and to improve access to treatment in low- and middle-income countries (LMICs). Summary: From 2003 to 2016, incidence rates of treated ESKD were relatively stable in many higher income countries but rose substantially predominantly in East and Southeast Asia. The prevalence of treated ESKD has increased worldwide, likely due to improving ESKD survival, population demographic shifts, higher prevalence of ESKD risk factors, and increasing KRT access in countries with growing economies. Unadjusted 5-year survival of ESKD patients on KRT was 41% in the USA, 48% in Europe, and 60% in Japan. Dialysis is the predominant KRT in most countries, with hemodialysis being the most common modality. Variations in dialysis practice patterns account for some of the differences in survival outcomes globally. Worldwide, there is a greater prevalence of KRT at higher income levels, and the number of people who die prematurely because of lack of KRT access is estimated at up to 3 times higher than the number who receive treatment. Key Messages: Many people worldwide in need of KRT as a life-sustaining treatment do not receive it, mostly in LMICs where health care resources are severely limited. This large treatment gap demands a focus on population-based prevention strategies and development of affordable and cost-effective KRT. Achieving global equity in KRT access will require concerted efforts in advocating effective public policy, health care delivery, workforce capacity, education, research, and support from the government, private sector, nongovernmental, and professional organizations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000514550

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 84 references

Cited by

Sorted by citations

Items 801–876 of 876

Related

See all

Metadata

Authors
Thurlow, J. S., Joshi, M., Yan, G., Norris, K. C., Agodoa, L. Y., Yuan, C. M., & Nee, R.
Affiliations
  • Uniformed Services University of the Health Sciences (US)
  • University of Virginia (US)
  • University of California, Los Angeles (US)
  • National Institutes of Health (US)
ORCID
Venue
American Journal of Nephrology
Publisher
S. Karger AG
Published
2021
Volume
52
Issue
2
Pages
98-107
ISSN
  • 0250-8095 (ISSN-L)
  • 1421-9670
DOI
10.1159/000514550
PMC
PMC8057343
OpenAlex
W3139528122
Semantic Scholar
05b07bab0110bf2b0dbec0353ad07b1b281fbf70
Cited by
855
References
84
Citations by year
2026: 141 · 2025: 207 · 2024: 214 · 2023: 170 · 2022: 104 · 2021: 17
FWCI
20.74
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Nephrology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health (Z99 DK999999, UL1TR000124, UL1TR001881)
  • National Institute on Aging (P30AG021684)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK112008)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
Keywords
end-stage renal disease, renal replacement therapy, dialysis, hemodialysis, regional variation, incidence and prevalence, survival, treatment gap, health care access, low- and middle-income countries, health disparities, global equity, health policy
MeSH terms
Africa, Arteriovenous Shunt, Surgical, China, Developing Countries, Renal Dialysis, Humans, India, Kidney Failure, Chronic, United States, Global Health, Incidence, Prevalence, Survival Rate, Renal Replacement Therapy, Developed Countries, Healthcare Disparities

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review